Glucagon-Like Peptide-1 and its Cardiovascular Effects

被引：19

作者：

Heo, Kyung-Sun ^{[1
]}

Fujiwara, Keigi ^{[1
]}

Abe, Jun-ichi ^{[1
]}

机构：

[1] Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY 14642 USA

来源：

CURRENT ATHEROSCLEROSIS REPORTS | 2012年 / 14卷 / 05期

关键词：

Cardiovascular disease; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Glucagon-like peptide-1 receptor; Incretins; Myocardial infarction; Type 2 diabetes mellitus; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; TYPE-2; DIABETES-MELLITUS; MYOCARDIAL GLUCOSE-UPTAKE; OPEN-LABEL TRIAL; GLYCEMIC CONTROL; PARALLEL-GROUP; DILATED CARDIOMYOPATHY; REPERFUSION INJURY; RECEPTOR FAMILY; CONSCIOUS DOGS;

D O I：

10.1007/s11883-012-0265-9

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Recently, the crucial role of GLP-1 in cardiovascular disease has been suggested by both preclinical and clinical studies. In vivo and in vitro studies have demonstrated cardio-protective effects of GLP-1 by activating cell survival signal pathways, which have greatly reduced ischemia/reperfusion injury and also cardiac dysfunction in various congestive heart failure animal models. Clinically, beneficial effects of GLP-1 have been shown in patients with myocardial infarction, hypertension, and heart failure, and 2 classes of incretin enhancers, GLP-1 receptor agonists and DPP-4 inhibitors, are currently available for the treatment of type 2 diabetes mellitus. In this review, we will summarize the role of incretins in various cardiovascular events such as hypertension and heart failure and postprandial lipoprotein secretion, and discuss their molecular mechanisms and potentials as a new therapeutic as well as preventive drug type for reducing cardiovascular events in both diabetic and nondiabetic patients.

引用

页码：422 / 428

页数：7

共 61 条

[1] Biology of incretins: GLP-1 and GIP [J].

Baggio, Laurie L. ;

Drucker, Daniel J. .

GASTROENTEROLOGY, 2007, 132 (06) :2131-2157

[2] Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways [J].

Ban, Kiwon ;

Noyan-Ashraf, M. Hossein ;

Hoefer, Judith ;

Bolz, Steffen-Sebastian ;

Drucker, Daniel J. ;

Husain, Mansoor .

CIRCULATION, 2008, 117 (18) :2340-2350

[3] Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride [J].

Basu, Ananda ;

Charkoudian, Nisha ;

Schrage, William ;

Rizza, Robert A. ;

Basu, Rita ;

Joyner, Michael J. .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 293 (05) :E1289-E1295

[4] Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase-Mediated, Nitric Oxide-Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy [J].

Bhashyam, Siva ;

Fields, Anjali V. ;

Patterson, Brandy ;

Testani, Jeffrey M. ;

Chen, Li ;

Shen, You-tang ;

Shannon, Richard P. .

CIRCULATION-HEART FAILURE, 2010, 3 (04) :512-521

[5] Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury [J].

Bose, AK ;

Mocanu, MM ;

Carr, RD ;

Brand, CL ;

Yellon, DM .

DIABETES, 2005, 54 (01) :146-151

[6]

Brown J C, 1975, Recent Prog Horm Res, V31, P487

[7] Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor [J].

Bullock, BP ;

Heller, RS ;

Habener, JF .

ENDOCRINOLOGY, 1996, 137 (07) :2968-2978

[8] Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].

Buse, John B. ;

Rosenstock, Julio ;

Sesti, Giorgio ;

Schmidt, Wolfgang E. ;

Montanya, Eduard ;

Brett, Jason H. ;

Zychma, Marcin ;

Blonde, Lawrence .

LANCET, 2009, 374 (9683) :39-47

[9] DIVERGENT TISSUE-SPECIFIC AND DEVELOPMENTAL EXPRESSION OF RECEPTORS FOR GLUCAGON AND GLUCAGON-LIKE PEPTIDE-1 IN THE MOUSE [J].

CAMPOS, RV ;

LEE, YC ;

DRUCKER, DJ .

ENDOCRINOLOGY, 1994, 134 (05) :2156-2164

[10] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].

Charbonnel, Bernard ;

Karasik, Avraham ;

Liu, Ji ;

Wu, Mei ;

Meininger, Gary .

DIABETES CARE, 2006, 29 (12) :2638-2643

← 1 2 3 4 5 6 7 →